APP下载

Synthesis and Crystal Structure of N-((3-(2-nitrophenyl) propanoyl)oxy)-N-phenylbenzamide①

2015-08-31LIUXiao-Feng,ZHANGYang,LIJing等

结构化学 2015年5期

Synthesis and Crystal Structure of N-((3-(2-nitrophenyl) propanoyl)oxy)-N-phenylbenzamide①

LIU Xiao-FengaZHANG Yangb, cLI Jingb, cZHAO Jing-Sib, cXI Nab, cHE Dianb②a(School of Life Science and Engineering,Lanzhou University of Technology, Lanzhou 730050, China)

b(Institute of Medicinal Chemistry, School of Pharmaceutical Science, Lanzhou University, Lanzhou 730000, China)

c(Lanzhou Way Biological Science and Technology Development Co., LTD)

The title compound N-((3-(2-nitrophenyl) propanoyl)oxy)-N-phenylbenzamide (C22H18N2O5, Mr= 390.38) was synthesized with nitrobenzene as the starting materials and structurally characterized by1H NMR,13C NMR, IR, H RMS(E-SI) and single-crystal X-ray diffraction. The crystalline structure of the title compound was studied in detail. The single-crystal X-ray diffraction revealed that the compound crystallizes in monoclinic, space group P21/n, with a = 14.4481(7), b = 8.0089(5), c = 16.6808(9) Å, α = 90.00(5), β = 100.069(5), γ = 90.00(5)°, Mr= 390.38, V = 1900.46(18) Å3, Z = 4, Dc= 1.364 g/cm-3, μ = 0.098, F(000) = 816.0, the final R = 0.0530 and wR = 0.1141 for 2525 observed reflections (I > 2σ(I)), R(all data) = 0.0813, wR(all data)= 0.1335, completeness to theta of 26.020 is 99.8% and GOF = 1.085. The crystal structure contains three branched chains with its center placed at the midpoint of N. The phenyl ring (C(8)~C(13))makes a dihedral angle of 83.5(1) ℃ with the phenyl ring (C(1)~C(6)), and 80.5(1) ℃ with the nitro-substituted benzene ring (C(17)~C(22)), indicating that the three rings are not coplanar. Hydrogen bonds (C(10)-H(10)··O(3)), (C(15)-H(15B)··O(4) and C(16)-H(16B)··O(4)) together with π-π stacking interactions stabilize the structure of the molecule. The preliminary biological test shows that the title compound has good antitumor activity against A549 in vitro with the IC50 value of 3.17 μmol.

crystal structure, synthesis, N-((3-(2-nitrophenyl) propanoyl)oxy)-N-phenylbenzamide;

1 INTRODUCTION

As we all know, histone deacetylase inhibitors (HDACi) play an important role in the treatment of cancers, and the hydroxamic acids are widely studied[1-4]. It’s known to all that parts of the histone deacetylases are Zn-dependent enzymes, and the hydroxamic acid can interact with the Zn+ion at the bottom of the active binding site of enzyme. However, the hydroxamic acid group has poor stability, thus the phenyl substituted hydroxamate compound was designed and synthesized. Owing to the introduction of phenyl, the lipophilicity of the compounds was increased. In overall, lipophilicityleads to increase of hydrophobic interaction between HDAC and HDAC inhibitors, improving the inhibitory activity. The title compound was synthesized as a prodrug of hydroxamic acids, and it is significant in the clinical therapy.

Owing to the primitive state of tumor vasculature,solid tumors often develop regions of chronic or acute hypoxia as a result of chronic or transient deficiency of blood flow[5]. Hypoxic tumor cells are known to have greater capacity for reductive reactions as compared to well-oxygenated normal cells[6, 7]. This unique feature of solid tumors provides an attractive target for selective anticancer chemotherapy. The title compound was synthesized as a prodrug. Scheme 1 shows the potential mechanism of the activation of the compound[8]. After reduction in the hypoxic tumor cells, the reduced product could undergo facile cyclization reaction forming lactam, and the active moiety N-hydroxy-N-phenylbenzamide is released[9]. Thus, the design improves the selectivity of the compound and reduces the cytotoxicity. Herein, we report the synthesis, crystal structure and biological activities of the title compound.

In this study, the title compound was obtained by the reduction of nitrobenzene and raney nickel was used as the catalyst[10, 11]. And after that two steps of acylation were used to synthesize the target compound. The reaction was easy to operate in lab with low pollution. The synthetic route is shown in Scheme 2 according to the literature[12, 13].

Scheme 1. Mechanism of the activation of the title compound

2 EXPERIMENTAL

2. 1 Instruments and reagents

The melting point was measured on an electrothermal PIF YRT-3 device without correction.1H NMR and13C NMR (δ ppm) spectra were acquired on a Varian Mercury (400MHz) using TMS as the internal standard. IR spectra were determined on NEXUS670 FT-IR (Nicolet). Mass spectra were recorded on a VGZAB-HS (70 ev) spectrometer with ESI source as ionization. X-ray diffraction was performed using a Bruker APEXⅡ CCD diffractometer.

Unless otherwise noted, all materials were obtained from commercial suppliers and purified by standard procedures. All the reactions were monitored by analytical thin-layer chromatography (TLC) and silica gel F254was used in TLC. The crystals for single-crystal X-ray analysis were grown by the slow evaporation of solution of methanolethyl-acetate (1:3 v/v).

2. 2 Preparation of N-hydroxybenzamine (2)

We synthesized the compound according to the literature[14]. When the raney nickel was used as catalyst, the product was easier to separate and the reaction rate was easier to control. The nitrobenzene was dissolved in the mixed solvent (50% ethanol, 50% 1,2-dichloroethane, and 50 mL),followed by the adding of a small spoon of raney nickel. Then the hydrazine hydrate (2 g, 80%, 40 mmol) was added dropwise. The mixture was stirred for 30 minutes, then the raney nickel was collected by filtration and the solution was removed under reduced pressure at 45 ℃. Residual liquid was extracted by dichloromethane (30 mL × 3) and water (30 mL). Organic layer was combined and dried by anhydrous magnesium sulfate, then dichloromethane was steamed out under educed pressure at 45 ℃,and N-hydroxybenzamine was obtained as white needle solid.

2. 3 Synthesis of N-hydroxy-N-phenylbenzamide (4)Compound 2 (10 mmol) was dissolved in dichloromethane (45 mL) at 0 ℃ and the sodium bicarbonate (1.5 equivalent) was added. Subsequently,compound 3 (10 mmol) in dichloromethane was added dropwise. The mixture was stirred for 2 h and then the sodium bicarbonate was removed by filtration and the solution was steamed out under reduced pressure. N-hexane was added to the residual liquid and compound 4 was separated as white solid. Yield: 79%.1H NMR (400MHz,DMSO-d6) δ: 10.73(s, 1H), 7.64(d. J = 6.8Hz, 2H),7.57(d, J = 8.0Hz, 2H), 7.49~7.37(m, 5H), 7.22~7.18(m, 1H).13C NMR (100MHz DMSO-d6) δ: 167.9, 142.1, 135.5, 130.2, 128.3, 127.8, 125.5,122.1. IR (KBr) (cm-1): 3181(-OH), 2881(-C-H),1624(-C=O), 1494(Ar), 1373(Ar).

2. 4 Synthesis of the title compound

The sodium bicarbonate (1.5 equivalent) was added to the solution (10 mmol compound 4 and 40 mL dichloromethane) at room temperature. Then the solution of compound 5 was added dropwise. The mixture was stirred and monitored by TLC. The sodium bicarbonate was removed by filtration after the reaction was accomplished and the solution was steamed out under reduced pressure. Compound 6 was separated as yellowish solid after adding methanol. Yield: 66%; mp: 96~98 ℃.1H NMR (400 MHz, CDCl3): 7.96 (dd, J1= 1.2 Hz, J2= 8.8 Hz, 1H), 7.53~7.48 (m, 3H), 7.40~7.32 (m, 3H),7.30~7.24 (m, 7H), 3.25 (t, J1= 7.5 Hz, J2= 7.5 Hz,2H), 2.89 (t, J1= 8.0 Hz, J2= 7.2 Hz, 2H);13C NMR (100 MHz, CDCl3): 169.7, 166.7, 148.9, 140.4,134.7, 133.4, 133.1, 132.3, 131.1, 129.2 (2C), 128.7 (3C), 128.4, 128.1 (2C), 127.8, 126.8, 125.0, 32.2 (-CH2CH2(C=O)-), 28.1 (-CH2CH2(C=O)-). H RMS (ESI): (M+H)+391.1288 (calculated 391.1281), error = 1.8 ppm; IR (KBr) ν: 1675 (-COO-), 1609 (C=O),1533 (NO2), 1350 (NR3) cm-1.

Scheme 2. Synthesis of the title compoundReagents and conditions: (a) NH2NH2·H2O, Raney nickel, stir;(b) CH2Cl2, NaHCO3, O ℃; (c) CH2Cl2, NaHCO3, rt, stir

2. 5 Structure determination

A clear light colourless crystal of the title compound with dimensions of 0.37mm × 0.34mm × 0.28mm was selected for X-ray diffraction analysis. X-ray crystallographic data were collected at 293(2)K. All measurements were made on a Super Nova,Dual, Cu at zero, Eos diffractometer equipped with a graphite-monochromated MoKa radiation (λ = 0.71070 Å) situated in the incident beam. In the range of 6.14≤2θ≤52.04º (-17≤h≤16, -9≤k≤9,-20≤l≤19), a total of 7826 reflections were collected, of which 3741 were independent (Rint= 0.0443). The structure was solved by direct methods using SHELXS-97 and refined by the SHELXL-97[15, 16]package using Least-squares minimisation. All non-hydrogen atoms were refined with anisotropic thermal parameters. Besides, all hydrogen atoms were located theoretically and refined withriding coordinate parameters. The final R (reflections) = 0.0530, wR = 0.1141 (w = 1/[σ2(Fo2) + (0.0372P)2+ 0.2728P], where P = (Fo2+ 2Fc2)/3), S = 1.085, (Δ/σ)max= 0.000, (Δρ)max= 0.151 and (Δρ)min= -0.191 e/Å3.

2. 6 MTT assay to measure the cell

growth inhibition in vitro

The inhibitory effects on cell proliferation of target compound were investigated by the MTT method. A549, Hela, MEL, and MCF-7 were chosen for the experiment. All cell lines were maintained at 37 ℃ in 5% CO2in DMEM medium, supplemented of cytotoxin causing an inhibition of 50% in the viability of the cells compared with the control cell culture.

3 RESULTS AND DISCUSSION

with 10% fetal calf serum. The logarithm vegetal period cells were inoculated at the appropriate concentration (100 μL per well) into 96-well plates while the marginal wells should be omitted. Then the cells were pre-incubated for 24 h. The solutions of the compounds with the corresponding concentration were applied carefully on the monolayers of cells for 48 h. After that, 10 μL of MTT stock solution (5 mg/mL in PBS) was added in each well and the plate was incubated for 4 h. The blue-coloured formazan was dissolved in 10 min. The absorbance was determined at 490 nm to calculate the IC50which was defined as the amount

We synthesized N-((3-(2-nitrophenyl) propanoyl)oxy)-N-phenylbenzamide with nitrobenzene as the starting materials. Firstly, N-phenylhydroxylamine was obtained by the reduction of nitrobenzene, then compound 3 was generated by the acylation of compound 2 in low temperature. And the title compound was obtained through oxygen acylation. The synthetic route is summarized in Scheme 1. The structure of the title compound was confirmed by1H NMR,13C NMR, IR, and H RMS (ESI).

The structure of the title compound was finally confirmed by single-crystal X-ray diffraction, as shown in Fig. 1. The selected bond lengths and bond angles are listed in Table 1 and the hydrogen bond geometry in Table 2. The hydrogen bonds of the molecular structure of the title compound are shown in Fig. 2. Bond lengths and bond angles agree well with the values reported[17-19].

Fig. 1. Structure of the title compound

Fig. 2. Molecular structure of the title compound showing hydrogen bonds

Table 1. Selected Bond Lengths (Å) and Bond Angles (°) for the Title Compound

Table 2. Hydrogen Bond Lengths (Å) and Bond Angles (°)

As shown in Fig. 1, the crystal structure contains three branched chains with its center placed at the midpoint of N. The phenyl ring (C(8)~C(13))makes a dihedral angle of 83.5(1) ℃ with the phenyl ring (C(1)~C(6)), and 80.5(1) with℃ the nitrosubstituted benzene ring (C(17)~C(22)). The sum of C(8)-C(7)-O(1), O(1)-C(7)-N(1) and C(8)-C(7)-N(1) angles is 360°, which indicates the sp2hybridization state of the C(7) atom. From Table 1, we find that the C(7)-N(1) bond (1.373(3) Å) is shorter than the typical C-N (1.47 Å) and close to the typical C=N (1.35 Å) because of the p-π conjugating effect. There are one extramolecular (C(10)-H(10)··O(3)) hydrogen bond and two intramolecular hydrogen bonds (C(15)- H(15B)··O(4),C(16)-H(16B)··O(4)) to be found, which play a major role in stabilizing the molecule.

Table 4. Inhibition of Cell Growth (μmol/L)

4 BIOLOGICAL ACTIVITIES

The synthetic compounds were evaluated for their antiproliferative activity against four different tumor cell lines with SAHA as a reference compound, with the results summarized in Table 4. The inhibitory activity of SAHA against these cells is in agreement with literature[20]and the National Cancer Institute Development Theraputic Program (NCI-DTP) data. The compound we have synthesized presented good inhibition profile against HeLa, MC-7, A549 and BEL-7402, which was equivalent with the positive group SAHA. The values of IC50were 7.15, 3.17,5.28 and 4.65 μM, respectively. What’s more, the inhibitory to A549 (IC50= 3.17 μmol/L) was the most outstanding, so this kind of compound was worth exploring, and further studies are underway to research the structure activity relationships and structural modifications.

REFERENCES

(1) Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: from bench to clinic. J. Med. Chem. 2008, 51, 1505-1530.

(2) Park, J. H.; Jung, Y.; Kim, T. Y.; Kim, S. G. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit Human tumor proliferation. Clin. Cancer Res. 2004, 10, 5271-5281.

(3) Nakagawa, M.; Oda, Y.; Eguchi, T.; Aishima, S.; Yao, T.; Hosoi, F.; Basaki, Y.; Ono, M.; Kuwano, M.; Tanaka, M.; Tsuneyoshi, M. Expression profile of class I histone deacetylases in human cancer tissues. Oncology Reports 2007, 18, 769-774.

(4) Witt, O.; Lindemann, R. HDAC inhibitors: magic bullets, dirty drugs or just another targeted therapy. Cancer Letters 2009, 280, 123-124.

(5) Tercel, M.; Wilson, W. R.; Anderson, R. F.; Denny, W. A. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. Journal of Medicinal Chemistry 1996, 39, 1084-1094.

(6) Denny, W. A.; Atwell, G. J.; Roberts, P. B.; Anderson, R. F.; Boyd, M.; Lock, C. J.; Wilson, W. R. Hypoxia-selective antitumor agents. 6. 4-(Alkylamino)nitroquinolines: a new class of hypoxia-selective cytotoxins. Journal of Medicinal Chemistry 1992, 35, 4832-4841.

(7) Brown, J. M.; Chaloupka, J.; Taylor, K. J.; Quedens-Case, C.; Alderman, J.; Greener, Y. Contrast-enhanced ultrasound for guidance of local tumor ablation. Ultrasound Med. Biol. 1999, 25, 1213-1219.

(8) Senter, P. D.; Marquardt, H.; Thomas, B. A.; Hammock, B. D.; Frank, I. S.; Svensson, H. P. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. Cancer Research 1996, 56, 1471-1474.

(9) Huynh, G. H.; Deen, D. F.; Szoka, F. C. Barriers to carrier mediated drug and gene delivery to brain tumors. J. Controlled Release 2006, 110, 236-259.

(10) Krüger, S.; Meier, C. Synthesis of site-specific damaged DNA strands by 8-(acetylarylamino)-2΄-deoxyguanosine adducts and effects on various DNA polymerases. Eur. J. Org. Chem. 2013, 20, 1158-1169.

(11) Petrukhin, O. M.; Spivakov, B. Y.; Morgalyuk, V. P.; Malofeeva, G. I.; Kuzovkina, E. V.; Novikov, A. P. Solid-phase extraction of plutonium(IV)anamericium(III) using N-benzoylphenylhydroxylamine and its derivatives. Russ J. Inorg. Chem. 2011, 56, 1839-1846.

(12) Liu, S.; Wang, Y.; Yang, X.; Jiang, J. Selective reduction of nitroarenes to narylhydroxylamines by use of Zn in a CO2-H2O system, promoted by ultrasound. Res. Chem. 2012, 38, 2471-2478.

(13) Ren, P.; Dong, T.; Wu, S. Synthesis of N-arylhydroxylamines by antimony-catalyzed reduction of nitroarenes. Synthetic Commu. 1997, 27, 1547-1552.

(14) Anil Kumar, N. V.; Mantelingu, K.; Rangappa, K. S. Synthesis and characterization of adenosine adducts of arylamines. Nucleosides, Nucleotides & Nucleic Acids 2002, 21, 463-467.

(15) Sheldrick, G. M. SHELXS97, Program for Crystal Structure Solution. University of Göttingen, Germany 1997.

(16) Sheldrick, G. M. SHELXL97, Program for Crystal Structure Refinement. University of Göttingen, Germany 1997.

(17) Zhang, H.; Qu, D.; Ma, J. N-(2-Chlorophenyl)-1-phenyl formamido 3-(2-nitrophenyl) propanoate. Acta Cryst. 2012, 68, 3067-3072.

(18) Ma, J.; Ma, Y.; He, D. N-(4-chlorobenzoyl)-N-(2-chlorophenyl)-O-[2-(2-nitrophen-yl)acetyl]hydroxylamine. Acta Cryst. 2012, 68, 3067-3072.

(19) Zhang, K.; He, D. N-benzoyl-N-(3-methylphenyl)-O-[2-(2-nitrophenyl)acetyl]hydroxylamine. Acta Cryst. 2011, 67, 1966-1971.

(20) Sumanadasa, S. D.; Goodman, C. D.; Lucke, A. J.; Skinner-Adams, T. Antimalarial activity of the anticancerhistone deacetylase inhibitor SB939. Antimicrob. Agents Ch. 2012, 56, 3849-3856.

Received 25 December 2014; accepted 2 February 2015 (CCDC 991799)

① Supported by the Lanzhou Science and Technology Bureau Program Funds (2013-4-79, 2014-1-174, 2014-1-214)

② Corresponding author. Born in 1970. Tel: +86-931-13008738922, Fax: +86-0931-8915685, E-mail: hed@lzu.edu.cn

10.14102/j.cnki.0254-5861.2011-0615


登录APP查看全文